{"id":17894,"date":"2014-04-15T04:30:00","date_gmt":"2014-04-15T02:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/boehringer-ingelheim-vuole-lanciare-oltre-10-nuovi-farmaci-entro-2016\/"},"modified":"2014-04-15T04:30:00","modified_gmt":"2014-04-15T02:30:00","slug":"boehringer-ingelheim-vuole-lanciare-oltre-10-nuovi-farmaci-entro-2016","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/boehringer-ingelheim-vuole-lanciare-oltre-10-nuovi-farmaci-entro-2016\/","title":{"rendered":"Boehringer Ingelheim: wants to launch over 10 new drugs by 2016"},"content":{"rendered":"

 \"\"<\/font><\/span><\/p>\n

Stable profit estimate this year, turnover in line with 2013 (Il Sole 24 Ore Radiocor) \u2013 Ingelheim, 15 April \u2013 Boehringer Ingelheim (BI), the German pharmaceutical company among the top twenty in the world, intends to grow "organically, sustainable, in the long term and standing alone". Also excluded are "major acquisitions". Thus the president Andreas Barner, who speaking to journalists on the sidelines of the budget meeting, forecast for this year a "more or less stable" profit compared to 2013 (1.32 billion) and a turnover "similar" to the last year (14.1 billion). After launching 3 new products and 8 filings in 2013, BI plans to launch more than 10 new drugs by 2016 for eight diseases: diabetes, chronic obstructive pulmonary disease, asthma, lung cancer, idiopathic pulmonary fibrosis, a rare form of leukemia and the treatment and prevention of deep vein thrombosis and pulmonary embolism.<\/p>\n

<\/font><\/span><\/p>\n

pal-(RADIOCOR) 15-04-14 14:57:14 (0399) 5 NNNN<\/span>  <\/span><\/span>The sun<\/span><\/sup><\/b>24 HOURS<\/span><\/b><\/p>\n

<\/span><\/p>\n

<\/p>\n

 <\/font><\/p>\n

<\/span><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

    Stima utile stabile quest’anno, fatturato in linea con 2013 (Il Sole 24 Ore Radiocor) – Ingelheim, 15 apr – Boehringer Ingelheim (BI), l’azienda farmaceutica tedesca tra le prime venti al mondo, intende crescere "in modo organico, sostenibile, nel lungo termine e restando da sola". Sono inoltre escluse "grandi acquisizioni". Cosi’ il presidente Andreas Barner, …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17894"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}